JP2013517487A5 - - Google Patents

Download PDF

Info

Publication number
JP2013517487A5
JP2013517487A5 JP2012549291A JP2012549291A JP2013517487A5 JP 2013517487 A5 JP2013517487 A5 JP 2013517487A5 JP 2012549291 A JP2012549291 A JP 2012549291A JP 2012549291 A JP2012549291 A JP 2012549291A JP 2013517487 A5 JP2013517487 A5 JP 2013517487A5
Authority
JP
Japan
Prior art keywords
tumor
cancer
antigen
cells
associated carbohydrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2012549291A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013517487A (ja
Filing date
Publication date
Priority claimed from EP10000527A external-priority patent/EP2347769A1/en
Application filed filed Critical
Publication of JP2013517487A publication Critical patent/JP2013517487A/ja
Publication of JP2013517487A5 publication Critical patent/JP2013517487A5/ja
Ceased legal-status Critical Current

Links

JP2012549291A 2010-01-20 2011-01-20 がん幹細胞マーカーおよびその使用 Ceased JP2013517487A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US29673810P 2010-01-20 2010-01-20
US61/296,738 2010-01-20
EP10000527.1 2010-01-20
EP10000527A EP2347769A1 (en) 2010-01-20 2010-01-20 Cancer stem cell markers and uses thereof
PCT/EP2011/000217 WO2011089004A1 (en) 2010-01-20 2011-01-20 Cancer stem cell markers and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015253064A Division JP2016047848A (ja) 2010-01-20 2015-12-25 がん幹細胞マーカーおよびその使用

Publications (2)

Publication Number Publication Date
JP2013517487A JP2013517487A (ja) 2013-05-16
JP2013517487A5 true JP2013517487A5 (enExample) 2014-02-06

Family

ID=42173400

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012549291A Ceased JP2013517487A (ja) 2010-01-20 2011-01-20 がん幹細胞マーカーおよびその使用
JP2015253064A Withdrawn JP2016047848A (ja) 2010-01-20 2015-12-25 がん幹細胞マーカーおよびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015253064A Withdrawn JP2016047848A (ja) 2010-01-20 2015-12-25 がん幹細胞マーカーおよびその使用

Country Status (8)

Country Link
US (1) US20120294859A1 (enExample)
EP (2) EP2347769A1 (enExample)
JP (2) JP2013517487A (enExample)
CN (1) CN102753199A (enExample)
AU (1) AU2011208874B2 (enExample)
BR (1) BR112012018132A2 (enExample)
CA (1) CA2786212A1 (enExample)
WO (1) WO2011089004A1 (enExample)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7960139B2 (en) 2007-03-23 2011-06-14 Academia Sinica Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
JP5986745B2 (ja) 2008-07-15 2016-09-06 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ Ｐｔｆｅ様のアルミニウム・コート・ガラススライド上のグリカンアレイおよび関連する方法
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
WO2011130332A1 (en) 2010-04-12 2011-10-20 Academia Sinica Glycan arrays for high throughput screening of viruses
US9778264B2 (en) 2010-09-03 2017-10-03 Abbvie Stemcentrx Llc Identification and enrichment of cell subpopulations
SG189212A1 (en) 2010-09-03 2013-05-31 Stem Centrx Inc Identification and enrichment of cell subpopulations
WO2012039430A1 (ja) * 2010-09-21 2012-03-29 株式会社Ｇｐバイオサイエンス がん幹細胞の単離方法
US10130714B2 (en) 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
WO2014031498A1 (en) 2012-08-18 2014-02-27 Academia Sinica Cell-permeable probes for identification and imaging of sialidases
US20160025717A1 (en) 2013-03-14 2016-01-28 Emory University Hyposialylation disorders
US10086054B2 (en) 2013-06-26 2018-10-02 Academia Sinica RM2 antigens and use thereof
WO2014210564A1 (en) 2013-06-27 2014-12-31 Academia Sinica Glycan conjugates and use thereof
JP6486368B2 (ja) 2013-09-06 2019-03-20 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ 改変されたグリコシル基を含む糖脂質を用いたヒトｉＮＫＴ細胞の活性化
RU2666141C2 (ru) 2013-09-17 2018-09-06 Оби Фарма, Инк. Композиции углеводной вакцины для индукции иммунного ответа и их применение при лечении рака
TW201620939A (zh) 2014-01-16 2016-06-16 中央研究院 治療及檢測癌症之組合物及方法
US10150818B2 (en) 2014-01-16 2018-12-11 Academia Sinica Compositions and methods for treatment and detection of cancers
EP3129767B1 (en) 2014-03-27 2021-09-01 Academia Sinica Reactive labelling compounds and uses thereof
US10023651B2 (en) 2014-04-18 2018-07-17 The Research Foundation For The State University Of New York Humanized anti-TF-antigen antibodies
AU2015247358B2 (en) * 2014-04-18 2020-02-27 The Research Foundation For The State University Of New York Humanized anti-TF-antigen antibodies
CN103969437B (zh) * 2014-04-22 2017-03-22 广州恒泰生物科技有限公司 用于卵巢癌早中期快速诊断试剂盒的制备方法
AU2015267045B2 (en) 2014-05-27 2021-02-25 Academia Sinica Anti-HER2 glycoantibodies and uses thereof
DK3149045T3 (da) 2014-05-27 2023-03-06 Academia Sinica Sammensætninger og fremgangsmåder vedrørende universelle glycoformer til forbedret antistofeffekt
US10118969B2 (en) 2014-05-27 2018-11-06 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
KR20170003720A (ko) 2014-05-27 2017-01-09 아카데미아 시니카 항-ｃｄ20 글리코항체 및 이의 용도
JP7063538B2 (ja) 2014-05-28 2022-05-09 アカデミア シニカ 抗ＴＮＦα糖操作抗体群およびその使用
EP3191500A4 (en) 2014-09-08 2018-04-11 Academia Sinica HUMAN iNKT CELL ACTIVATION USING GLYCOLIPIDS
US20170306046A1 (en) 2014-11-12 2017-10-26 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
US10495645B2 (en) 2015-01-16 2019-12-03 Academia Sinica Cancer markers and methods of use thereof
US9975965B2 (en) 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers
US10342858B2 (en) 2015-01-24 2019-07-09 Academia Sinica Glycan conjugates and methods of use thereof
KR102630294B1 (ko) * 2015-01-24 2024-01-26 아카데미아 시니카 암 마커 및 이를 사용하는 방법
US10493087B2 (en) 2015-02-25 2019-12-03 The United States of America, as represented by National Institute of Health Sialylation-increasing therapies for diseases associated with oxidative stress
JP2018532990A (ja) 2015-09-04 2018-11-08 オービーアイ ファーマ，インコーポレイテッド グリカンアレイおよび使用の方法
CN108463248B (zh) 2015-11-12 2022-10-21 西雅图基因公司 聚糖相互作用化合物及使用方法
WO2017100796A1 (en) * 2015-12-11 2017-06-15 SINACA, Academia Modulation of globoseries glycosphingolipid synthesis and cancer biomarkers
AU2017231749A1 (en) 2016-03-08 2018-09-20 Academia Sinica Methods for modular synthesis of N-glycans and arrays thereof
US10980894B2 (en) 2016-03-29 2021-04-20 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
US11041017B2 (en) 2016-03-29 2021-06-22 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
KR20250048399A (ko) 2016-04-22 2025-04-08 오비아이 파머 인코퍼레이티드 글로보 계열 항원을 통한 면역 활성화 또는 면역 조정에 의한 암 면역요법
WO2018022933A1 (en) 2016-07-27 2018-02-01 Obi Pharma, Inc. Immunogenic/therapeutic glycan compositions and uses thereof
EP3491026A4 (en) 2016-07-29 2020-07-29 OBI Pharma, Inc. HUMAN ANTIBODIES, PHARMACEUTICAL COMPOSITIONS AND PROCESSES
AU2017316663B2 (en) 2016-08-22 2024-02-22 CHO Pharma Inc. Antibodies, binding fragments, and methods of use
EP3541847A4 (en) 2016-11-17 2020-07-08 Seattle Genetics, Inc. COMPOUNDS INTERACTING WITH GLYCANE AND METHODS OF USE
MY195529A (en) 2016-11-18 2023-01-30 Astellas Pharma Inc Novel Anti-Human MUC1 Antibody Fab Fragment
JP2019535731A (ja) 2016-11-21 2019-12-12 オービーアイ ファーマ，インコーポレイテッド コンジュゲートさせた生物学的分子、医薬組成物及び方法
EP3589319A4 (en) 2017-03-03 2021-07-14 Seagen Inc. GLYCAN INTERACTING COMPOUNDS AND METHOD OF USE
CA3055438A1 (en) * 2017-03-29 2018-10-04 Glycotope Gmbh Multispecific antibody constructs binding to muc1 and cd3
TWI795415B (zh) 2017-07-07 2023-03-11 日商安斯泰來製藥股份有限公司 新穎的抗人類ＣＥＡＣＡＭ５抗體Ｆａｂ片段
BR122023024273A2 (pt) 2018-02-27 2024-02-20 Incyte Corporation Compostos imidazopirimidinas e triazolopirimidinas, seus usos, método para inibir uma atividade de um receptor de adenosina e composição farmacêutica dos mesmos
PT110722B (pt) * 2018-05-03 2021-08-17 Instituto De Patologia E Imunologia Molecular Da Univ Do Porto Ipatimup Uso de anticorpos para o antigénio thomsen-friedenreich num método e estojo para avaliação de instabilidade de microsatelites
WO2019221269A1 (ja) 2018-05-17 2019-11-21 アステラス製薬株式会社 抗ヒトＭＵＣ１抗体Ｆａｂフラグメント、ペプチドリンカー及び／又は配位子を含む複合体
HRP20240756T1 (hr) 2018-05-18 2024-09-13 Daiichi Sankyo Co., Ltd. Anti-muc1-eksatekan antitijelo-lijek konjugat
EP3810610A1 (en) 2018-05-18 2021-04-28 Incyte Corporation Fused pyrimidine derivatives as a2a / a2b inhibitors
US11203645B2 (en) 2018-06-27 2021-12-21 Obi Pharma, Inc. Glycosynthase variants for glycoprotein engineering and methods of use
AU2019297361B2 (en) 2018-07-05 2024-06-27 Incyte Corporation Fused pyrazine derivatives as A2A / A2B inhibitors
MY205764A (en) 2018-10-10 2024-11-12 Astellas Pharma Inc Pharmaceutical composition containing tagged site-antihuman antibody fab fragment complex
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
CN110161241A (zh) * 2019-04-30 2019-08-23 丁晓昆 一种快速检测生物组织切片cosmc基因突变试剂盒
KR20220137013A (ko) 2020-01-03 2022-10-11 인사이트 코포레이션 Cd73 억제제 및 a2a/a2b 아데노신 수용체 억제제 병용 요법
CR20220317A (es) 2020-01-03 2022-09-02 Incyte Corp Anticuerpos anti-cd73 y usos de estos
CN114249806B (zh) * 2020-03-18 2023-06-13 北京鼎成肽源生物技术有限公司 一种输卵管癌靶标抗原组合、输卵管癌靶标抗原刺激培养的ctl细胞及其应用
AU2021298824A1 (en) 2020-06-30 2023-01-19 Pentixapharm Ag Humanized antibodies against lewis Y
TW202241441A (zh) 2020-12-29 2022-11-01 美商英塞特公司 包含ａ２ａ／ａ２ｂ抑制劑、ｐｄ－１／ｐｄ－ｌ１抑制劑及抗ｃｄ７３抗體之組合療法
WO2022157422A1 (en) * 2021-01-25 2022-07-28 Kaivogen Oy Use of a fuc-alpha(1-2)-gal glycan structure as a biomarker for bladder cancer
WO2023023840A1 (en) * 2021-07-16 2023-03-02 Université de Montréal Novel tumor-specific antigens for cancer stem cells and uses thereof
CN113804531B (zh) * 2021-09-10 2024-02-06 北京大学 一种细胞高活性染色方法
CN115960169A (zh) * 2021-10-09 2023-04-14 清华大学深圳国际研究生院 特异性靶向非小细胞肺癌肿瘤干细胞的多肽及其应用
CN119955728A (zh) * 2022-08-01 2025-05-09 首都医科大学附属北京胸科医院 恶性表型大细胞肺癌细胞株及其应用
CN116718774A (zh) * 2023-07-07 2023-09-08 杭州准星医学科技有限公司 一种用于肿瘤体外诊断的试剂盒及其使用方法
CN121319187B (zh) * 2025-12-08 2026-03-17 宁波大学附属第一医院 一种与cd176蛋白结合的羊驼源纳米抗体及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6020145A (en) * 1989-06-30 2000-02-01 Bristol-Myers Squibb Company Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96
DE10256900A1 (de) 2002-11-29 2004-06-24 Nemod Immuntherapie Ag Tumorspezifische Erkennungsmoleküle
EP1654353B1 (en) 2003-08-18 2013-05-22 Glycotope GmbH Tumour cell lines nm-f9 (dsm acc2606) and nm-d4 (dsm acc2605), uses threreof
US7374755B2 (en) * 2004-07-26 2008-05-20 The Research Foundation Of State University Of New York Therapeutic use of anti-TF-Antigen antibody
WO2007079448A2 (en) * 2006-01-03 2007-07-12 University Of Georgia Research Foundation, Inc. Three component carbohydrate vaccine
WO2007140011A2 (en) * 2006-05-26 2007-12-06 The Government Of The United States Of America Erythroid progenitor cells and methods for producing parvovirus b19 therein

Similar Documents

Publication Publication Date Title
JP7274469B2 (ja) Ｃｄ３９／ｃｄ７３軸によるｔ細胞活性の回復
JP6491701B2 (ja) 新規モジュレーターと使用の方法
CN109970856B (zh) 抗lag-3抗体及其用途
Münz et al. Side-by-side analysis of five clinically tested anti-EpCAM monoclonal antibodies
JP2022537053A (ja) 抗ｔｉｇｉｔ抗体
JP2013544493A5 (enExample)
JP7450585B2 (ja) ＣＤ６６ｃに特異的に結合する抗体およびその用途
JP2017149720A5 (enExample)
EP2525832A1 (en) Cancer stem cell markers and uses thereof
JP2022507294A (ja) Ｃｄｃｐ１－標的化療法
WO2015161247A1 (en) Humanized anti-c16orf54 antibodies and methods of use thereof
WO2014068300A1 (en) Anti-s100a4 antibody molecules and their uses
JP2020125352A (ja) 抗−ｃｄ４３抗体およびその癌治療用途
CN114040774A (zh) 结合肿瘤组织用于诊断和治疗的抗体
CN110944665A (zh) 用于预防或治疗肺癌的amhrii结合化合物
JP7165855B2 (ja) 骨髄由来抑制細胞関連疾患の予防および治療用途
BR112020023380A2 (pt) anticorpo isolado ou um fragmento de ligação ao antígeno do mesmo, polinucleotídeo isolado, vetor recombinante, célula hospedeira, método para produzir um anticorpo ou um fragmento de aglutinação ao antígeno do mesmo e para tratar ou detectar câncer, conjugado de anticorpo ,e, composição farmacêutica
CN114907478A (zh) 结合lag-3的抗体及其用途
WO2024077774A1 (zh) 一种多功能重组抗体及其制备方法和应用
HK40113728A (zh) Claudin 18.2拮抗剂和pd-1/pd-l1轴抑制剂的组合疗法
CN118891287A (zh) 抗cd73的抗体及其应用
HK40009518B (en) Anti-lag-3 antibody and the use thereof
HK40009518A (en) Anti-lag-3 antibody and the use thereof
BR122024015952A2 (pt) Ligação de anticorpos especificamente à cd66c e utilização dos mesmos
BR112019009771B1 (pt) Ligação de anticorpos especificamente à cd66c e utilização dos mesmos